Vir Bio’s IPO Brings In $143M for Tests of Hepatitis B Drug and More

XCONOMY SAN FRANCISCO – Vir Biotechnology has joined the public markets, raising $142.9 million to support clinical tests of its infectious disease drugs.

Read the full press release here.